Top Tweets for #SARCLISA

4 months ago

La #FDA 🇺🇸 a repoussé de trois mois sa décision, qui devrait intervenir le 23 juillet, a indiqué #Sanofi 🇫🇷 Depuis son lancement en 2020, le #Sarclisa 💉, un #AnticorpsMonoclonal 💊, a été approuvé dans près de 60 pays et prescrit auprès de 70 000 patients dans le monde.

jyves94's tweet photo. La #FDA 🇺🇸 a repoussé de trois mois sa décision, qui devrait intervenir le 23 juillet, a indiqué #Sanofi 🇫🇷

Depuis son lancement en 2020, le #Sarclisa 💉, un #AnticorpsMonoclonal 💊, a été approuvé dans près de 60 pays et prescrit auprès de 70 000 patients dans le monde. https://t.co/37KPTa5VFD

246

Jyves94 🧬 @jyves94

4 months ago

Ce lundi, le géant #Sanofi 🇫🇷 a annoncé avoir obtenu l'approbation de la #CE 🇪🇺 de son traitement anticancéreux #Sarclisa 💉 en formulation sous-cutanée, via un injecteur portable, pour traiter le #MyélomeMultiple 🩸

Jyves94 🧬 @jyves94

4 months ago

Feu vert de l'#Europe 🇪🇺 pour le #Sarclisa 💉, 1er traitement anticancéreux par injecteur portable. Ce médicament a été développé afin de traiter le #MyélomeMultiple 🩸, un #Cancer causé par une production anormale de cellules à l'intérieur du plasma. https://t.co/b10HllKmG6

jyves94's tweet photo. Feu vert de l'#Europe 🇪🇺 pour le #Sarclisa 💉, 1er traitement anticancéreux par injecteur portable.

Ce médicament a été développé afin de traiter le #MyélomeMultiple 🩸, un #Cancer causé par une production anormale de cellules à l'intérieur du plasma.
https://t.co/b10HllKmG6 https://t.co/SyEspuaYYV

672

Jyves94 🧬 @jyves94

4 months ago

Rare Diseases @CheckOrphan

about 1 year ago

Sanofi’s Sarclisa Approved in the EU for the Treatment of Transplant-Eligible Newly Diagnosed Multiple Myeloma - For More Information Visit https://t.co/Sk4Pp4Bjqv #Multiple_Myeloma #Rare_Diseases @sanofi #MM #Sarclisa #OrphanDrugs #Drug_Research #Drug_Discovery

CheckOrphan's tweet photo. Sanofi’s Sarclisa Approved in the EU for the Treatment of Transplant-Eligible Newly Diagnosed Multiple Myeloma - For More Information Visit https://t.co/Sk4Pp4Bjqv #Multiple_Myeloma #Rare_Diseases @sanofi #MM #Sarclisa #OrphanDrugs #Drug_Research #Drug_Discovery https://t.co/2Xt9vQr6Nl

248

El GlobalFarma @ElGlobalEs

over 1 year ago

La CIPM financia 6⃣medicamentos en junio, entre ellos los huérfanos #Winrevair y #Akantior 📄El organismo ha comunicado nuevas indicaciones para #Jemperli (@GSK_ES), #Tagrisso (@AstraZeneca) y #Sarclisa (@sanofi) https://t.co/hdyT6iACCl

392

Jyves94 🧬 @jyves94

about 2 years ago

La #FDA 🇺🇸 a approuvé l’#Isatuximab (#Sarclisa) associé au #Bortézomib (#Velcade), au #Lénalidomide (#Revlimid) et à la #Dexaméthasone (#VRd) pour le traitement des patients atteints d’un #MyélomeMultiple 🩸 nouvellement diagnostiqué non éligible à une greffe https://t.co/8nFPaJ87NE

jyves94's tweet photo. La #FDA 🇺🇸 a approuvé l’#Isatuximab (#Sarclisa) associé au #Bortézomib (#Velcade), au #Lénalidomide (#Revlimid) et à la #Dexaméthasone (#VRd) pour le traitement des patients atteints d’un #MyélomeMultiple 🩸 nouvellement diagnostiqué non éligible à une greffe
https://t.co/8nFPaJ87NE

232

ACF Equity Research

@ACFER01

about 2 years ago

💉 Progress in #cancertreatment - $SNY to conduct UMBRELLA study - #Sanofi's #SARCLISA + $ALXO's evorpacept to combine to tackle relapsed #multiplemyeloma. #ALXO just dosed 1st patients in its PI/II. #CancerResearch #ClinicalTrials $VRTX $VCEL $SGMO $BCLI $GMDA $ICCM $BMY $GILD $ROG.SW $NVS @marklewismd @VincentRK @tmprowell @IceCureMedical @Roche @GileadSciences @Novartis @AstraZeneca Read our #ACFinsight https://t.co/emugU8I97e

ACF Equity Research

@ACFER01

about 2 years ago

The #oncology field is witnessing paradigm-changing advances in #cancertreatments. Is the offensive against cancer about to make a visible breakthrough? Read our #ACFinsight https://t.co/Nxfa2dBJEA @IceCureMedical @bmsnews @Roche @GileadSciences @Novartis @WHO @US_FDA @EMA_News

Myelom.Online @MyelomOnline

about 2 years ago

Multiples Myelom: Induktionstherapie mit Isatuximab (Sarclisa®) verbesserte das progressionsfreie Überleben https://t.co/vEppN3l7Yv #myelomonline #multiplesmyelom #induktionstherapie #isatuximab #sarclisa

MyelomOnline's tweet photo. Multiples Myelom: Induktionstherapie mit Isatuximab (Sarclisa®) verbesserte das progressionsfreie Überleben

https://t.co/vEppN3l7Yv

#myelomonline #multiplesmyelom #induktionstherapie #isatuximab #sarclisa https://t.co/oBEOfU5QVA

101

SmallCapKing - aka “Bob” @SmallCapBob2

over 2 years ago

Could this new Blo Blood Cancer Drug #Sarclisa developed by #Sanofi be a candidate to use the #Novavax adjuvant technology that preempted Sanofi to make a $1.2B investment in Novavax & take a 4.98% stake in $NVAX ? If so @Novavax would receive ROYALTIES https://t.co/itWKMtpSDp

588

Thaminda Ramanayake 🇺🇸 🇱🇰

@thaminda19

over 2 years ago

@adamfeuerstein Opportunity for $SNY to push #Sarclisa into I&I too - not too late yet…

194

Robert Z. Orlowski @Myeloma_Doc

over 4 years ago

#Myeloma Paper of the Day: Study of primary outcomes by 1q21+ status for isatuximab-treated patients with relapsed/refractory multiple #myeloma from ICARIA-MM and IKEMA studies suggests #Sarclisa may be especially useful for 1q21 #myeloma: https://t.co/bwmqEJgjsh.

$Myeloma_Doc's tweet photo. #Myeloma Paper of the Day: Study of primary outcomes by 1q21+ status for isatuximab-treated patients with relapsed/refractory multiple #myeloma from ICARIA-MM and IKEMA studies suggests #Sarclisa may be especially useful for 1q21 #myeloma: https://t.co/bwmqEJgjsh. https://t.co/vrMeFx7udO$

Consejeros @consejeroses

over 4 years ago

Blackstone Life Sciences colaborará con 300 M€ en el desarrollo del #Sarclisa, el tratamiento contra el #mieloma múltiple de @sanofi 👉 https://t.co/T4qswoqEOr #Empresas #Francia #Eurostoxx

consejeroses's tweet photo. Blackstone Life Sciences colaborará con 300 M€ en el desarrollo del #Sarclisa, el tratamiento contra el #mieloma múltiple de @sanofi 👉 https://t.co/T4qswoqEOr
#Empresas #Francia #Eurostoxx https://t.co/AxI9CcOXbT

FiercePharma

@FiercePharma

over 4 years ago

.@sanofi is going subcutaneous with its multiple myeloma drug #Sarclisa, and it's getting $300M worth of help from @blackstone to do it. #sanofi #multiplemyeloma https://t.co/FC1pHmxkuk

Robert Z. Orlowski @Myeloma_Doc

almost 5 years ago

#Myeloma Paper of the Day: IKEMA study analysis of #Sarclisa plus #Kyprolis/dex vs. #Kyprolis/dex finds preserved activity and superiority of triplet in patients with renal insufficiency (left graph) vs. those with normal renal function (right): https://t.co/kr3WIV6Swz.

Myeloma_Doc's tweet photo. #Myeloma Paper of the Day: IKEMA study analysis of #Sarclisa plus #Kyprolis/dex vs. #Kyprolis/dex finds preserved activity and superiority of triplet in patients with renal insufficiency (left graph) vs. those with normal renal function (right): https://t.co/kr3WIV6Swz. https://t.co/9SbJmWTZ06

The Patient Story

@Patient_Story

about 5 years ago

❌Learning treatment options often feels like swimming through alphabet soup. ✅Dr. Baljevic + Dr. Patel were gracious enough to lend their expertise for us on #myeloma👇 https://t.co/L2nNUCDjHm #mmsm #clinicaltrials #CARTcell #bispecifics #xpovio #pepaxto #sarclisa #blenrep

Robert Z. Orlowski @Myeloma_Doc

over 5 years ago

#Myeloma Paper of the Day: Phase III IKEMA study of #Sarclisa, #Kyprolis, and dex in relapsed #myeloma finds triplet improved PFS by 47% versus #Kyprolis/dex & had fewer discontinuations due to toxicities. https://t.co/UtII9cFGpG

Myeloma_Doc's tweet photo. #Myeloma Paper of the Day: Phase III IKEMA study of #Sarclisa, #Kyprolis, and dex in relapsed #myeloma finds triplet improved PFS by 47% versus #Kyprolis/dex & had fewer discontinuations due to toxicities. https://t.co/UtII9cFGpG https://t.co/PifkXK2Pxf

Robert Z. Orlowski @Myeloma_Doc

over 5 years ago

#Myeloma Paper of the Day: Final results of a phase 1b study of #Sarclisa short-duration fixed-volume infusion combination therapy for relapsed/refractory #myeloma finds safety and efficacy data comparable to what would be expected from phase 3 experience. https://t.co/jDr3zfsHAx

$Myeloma_Doc's tweet photo. #Myeloma Paper of the Day: Final results of a phase 1b study of #Sarclisa short-duration fixed-volume infusion combination therapy for relapsed/refractory #myeloma finds safety and efficacy data comparable to what would be expected from phase 3 experience. https://t.co/jDr3zfsHAx https://t.co/E2srgq4Eq7$

Robert Z. Orlowski @Myeloma_Doc

over 5 years ago

#Myeloma Paper of the Day: Subgroup analysis of ICARIA-MM trial in relapsed/refractory #myeloma patients with high-risk cytogenetics finds benefit for #Sarclisa/#Pomalyst/dex, especially for those with 1q21 amplification. https://t.co/GSAsqRNt6z

$Myeloma_Doc's tweet photo. #Myeloma Paper of the Day: Subgroup analysis of ICARIA-MM trial in relapsed/refractory #myeloma patients with high-risk cytogenetics finds benefit for #Sarclisa/#Pomalyst/dex, especially for those with 1q21 amplification. https://t.co/GSAsqRNt6z https://t.co/6C7z1HlKYO$

Robert Z. Orlowski @Myeloma_Doc

over 5 years ago

#Myeloma Paper of the Day: #Sarclisa plus #Pomalyst and dex shows consistent benefits in key patient subgroups with relapsed/refractory #myeloma. https://t.co/RluIkUFdFd

$Myeloma_Doc's tweet photo. #Myeloma Paper of the Day: #Sarclisa plus #Pomalyst and dex shows consistent benefits in key patient subgroups with relapsed/refractory #myeloma. https://t.co/RluIkUFdFd https://t.co/z08Cqtnm0P$

CDA-AMC @CDA_AMC

over 5 years ago

CADTH has issued a final recommendation that #isatuximab (#Sarclisa) be reimbursed w/ clinical criteria and/or conditions for the treatment of #MultipleMyeloma. Learn more 👉 https://t.co/efKU4GzksE

Top Tweets for #SARCLISA

Last Seen Hashtags on Sotwe

Trends for you

Most Popular Users